Follow us on LinkedIn to keep updated as keynote speakers are announced!
Professor of Cellular and Molecular Neuro-Oncology and Head of Brain Tumour Research Centre
(University of Portsmouth)
Paper presenting: 3D modelling for chemo sensitivity testing in neurology
Professor Pilkington has spent his entire career in brain tumour research, having started work on chemical neuro-carcinogenesis where he studied brain cancer stem cells and brain tumour development at the Middlesex Hospital Medical School in the early 1970s and subsequently spent 23 years at the Institute of Psychiatry, King’s College, London, latterly as Professor of Experimental Neuro-oncology.In 2003 he moved to the School of Pharmacy & Biomedical Sciences, University of Portsmouth, as Professor of Cellular & Molecular Neuro-oncology & Director of Research.
Over the years the research focus of his group has been development of models for the study of intrinsic brain tumours, elucidation of the mechanisms underlying diffuse local invasive behaviour in glioma, delivery systems for passage of agents across the blood-brain barrier (BBB) and development of novel strategies for mitochondrial mediation of apoptosis in glioma. He has published numerous papers on the results of his research on human glioma and has developed various “all human” three-dimensional in vitro models to study brain tumour invasion and the BBB. At the University of Portsmouth he has established an excellent suite of laboratories and a host of state-of-the-art equipment in which to accommodate the Brain Tumour Research Centre.
Combined in silico and 3D in vitro approaches for the accurate prediction of human drug induced liver injury
Clive completed a PhD on the role of the stress response as an early stage indicator of in vitro hepatotoxicity at The School of Pharmacy, University of London in 1998. He is Scientific Director at Cyprotex which is a subsidiary of Evotec.
Cyprotex specialises in ADME-Tox and Biosciences including both in vitro (laboratory experiments) and in silico (computer modelling) approaches.
Cyprotex serves the Pharmaceutical and Biotech, Cosmetics/Personal Care and Chemicals Industries as well as academia and not-for-profit organisations. Over 1700 organisations trust Cyprotex for their ADME-Tox and Bioscience research needs.
In 2015, we launched a new high throughput ADME laboratory at our Watertown facility in the US, and introduced our new Biosciences division which focuses on phenotypic based drug discovery and efficacy screening. Our core capabilities now include in vitro ADME-Tox, Biosciences, and PBPK and QSAR predictive modelling.
We focus heavily on R&D and our goal is to continually develop and improve approaches to more accurately predict human clinical outcome following exposure to a drug or chemical using robust in vitro methods combined with in silico technology.
Preclinical Hepatic Safety
Dominic joined AstraZeneca in 2014 and is Associate Director within Drug Safety & Metabolism (DSM, Cambridge UK), the Preclinical Hepatic Target Organ Lead and co-Chair of the Hepatic Safety Knowledge Group.
He sits on the AZ Post-Doc Committee which awards up to 50 post-doc positions each year, and has oversight of over 130 post-doc positions.
Until 2017, he was co-ordinator of the IMI1 consortium, MIP-DILI, and has been part of other EU initiatives (SAFE-T, SafeSciMET).
Prior to joining AZ, Dominic has 15 years of academic experience in translational hepatic drug safety from within the UK’s only MRC funded Centre for Drug Safety Science, at the University of Liverpool and secured funding of over £10M.
Dominic led a research group and trained & developed 14 PhD and 6 Master’s students, some of whom are current employees of AstraZeneca.
Dominic has authored over 100 peer-reviewed publications on drug safety. Dominic sits on the Scientific & Nominations Sub-committees of the British Toxicology Society and has been a member of a Medicines & Healthcare Regulatory Agency (MHRA) Expert Advisory Group.
To be confirmed
To be confirmed
To be confirmed